# A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer

> **NCT00454532** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bionovo** · enrollment: 27 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** BZL101

## Key facts

- **NCT ID:** NCT00454532
- **Lead sponsor:** Bionovo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2009-12
- **Final completion:** —
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2012-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454532, "A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00454532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*